Metastatic Breast Cancer Clinical Trials in Houston, Texas

16 studies are recruiting for metastatic breast cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

    This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    6 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07340541 on ClinicalTrials.gov

  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Methodist Hospital Research Institute, Houston, Texas
    Locations
    105 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT06324357 on ClinicalTrials.gov

  3. BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

    This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Md Anderson Cancer Center, Houston, Texas
    Locations
    14 in total
    Run by
    BeOne Medicines

    See if you can join NCT06756932 on ClinicalTrials.gov

  4. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas Md Anderson Cancer Center, Houston, Texas
    Locations
    62 in total
    Run by
    BeOne Medicines

    See if you can join NCT06120283 on ClinicalTrials.gov

  5. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    44 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06625775 on ClinicalTrials.gov

  6. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Houston Methodist Hospital Cancer Center, Houston, Texas
    Locations
    231 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

  7. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    10 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

  8. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

    This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

    Stage
    Not phased
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    4 in total
    Run by
    University of California, San Francisco

    See if you can join NCT05964504 on ClinicalTrials.gov

  9. Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

    The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

    Stage
    Not phased
    Ages
    18 and older
    Site
    The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT07179809 on ClinicalTrials.gov

  10. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    11 in total
    Run by
    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

  11. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, Houston, Texas
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  12. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treat…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    224 in total
    Run by
    LeonaBio

    See if you can join NCT05696626 on ClinicalTrials.gov

  13. Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

    This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments. Part…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Houston Methodist Neal Cancer Center, Houston, Texas
    Locations
    3 in total
    Run by
    The Methodist Hospital Research Institute

    See if you can join NCT05660083 on ClinicalTrials.gov

  14. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas M.D. Anderson Cancer Center, Houston, Texas
    Locations
    37 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

  15. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

    This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study wil…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    6 in total
    Run by
    Edgewood Oncology Inc.

    See if you can join NCT04872166 on ClinicalTrials.gov

  16. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Health Houston, Houston, Texas
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.